Seattle Genetics (SGEN) PT Raised to $105 at Leerink Partners

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/14/2026

1. DPZ
2. NVDA
3. DRS
4. GS
5. BAC
6. UNH
7. ORCL
8. AVAV
9. ACI
10. SPY

Go back to Seattle Genetics (SGEN) PT Raised to $105 at Leerink Partners

Seattle Genetics (SGEN) PT Raised to $98 at RBC Capital

October 1, 2018 11:14 AM EDT

RBC Capital analyst Kennen MacKay raised the price target on Seattle Genetics (NASDAQ: SGEN) to $98.00 (from $90.00) while maintaining a Outperform rating.

... More

Seattle Genetics (SGEN), Takeda Pharmaceutical Report Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS (Brentuximab Vedotin)

October 1, 2018 6:48 AM EDT

Seattle Genetics, Inc. (NASDAQ: SGEN) and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint. The trial demonstrated a statistically significant improvement in progression-free survival (PFS) of ADCETRIS (brentuximab vedotin) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) versus the control arm, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). ECHELON-2 is a... More